Top

Published in:

Open Access 01-06-2009

A New Vaccine for Tuberculosis: The Challenges of Development and Deployment

Authors: Helen A. Fletcher, Tony Hawkridge, Helen McShane

Published in: Journal of Bioethical Inquiry | Issue 2/2009

Abstract

Tuberculosis (TB) is one of the world’s leading causes of death due to infection and efforts to control TB would be substantially aided by the availability of an improved TB vaccine. There are currently nine new TB vaccines in clinical development, and the first efficacy trials are due to commence in 2009. There are many complex ethical issues which arise at all stages of TB vaccine development, from the need to conduct trials in developing countries to informed consent and the process of ethical review. While it is important that these issues are discussed, it may also be timely to consider the challenges which may arise if a vaccine in clinical development proves to be highly effective. We examine a number of scenarios where decisions on the deployment of a new TB vaccine may impact on the rights and liberty of the individual.

Alcorn, K. 2008. TB vaccine reduces new cases by almost 40% in people with HIV. Aidsmap News. 20 October. http://www.aidsmap.com/en/news/0C1FB0AF-9BC6-4A7A-8D47-7D8ABBD3C8E9.asp. Accessed 4 April 2009.

Baldwin, S.L., C. D'Souza, A.D. Roberts, B.P. Kelly, A.A. Frank, M.A. Lui, J.B. Ulmer, K. Huygen, D.M. McMurray, and I.M. Orme. 1998. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infection and Immunity 66(6): 2951–2959.PubMed

Brennan, M.J., U. Fruth, J. Milstien, R. Tiernan, S. de Andrade Nishioka, and L. Chocarro. 2007. Development of new tuberculosis vaccines: A global perspective on regulatory issues. PLoS Medicine 4(8): e252. doi:10.1371/journal.pmed.0040252.PubMedCrossRef

Buchbinder, S.P., D.V. Mehrotra, A. Duerr, D.W. Fitzgerald, R. Mogg, D. Li, P.B. Gilbert, J.R. Lama, M. Marmor, C. Del Rio, M.J. McElrath, D.R. Casimiro, K.M. Gottesdiener, J.A. Chodakewitz, L. Corey, and M.N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653): 1881–1893. doi:10.1016/S0140-6736(08)61591-3.PubMedCrossRef

Centers for Disease Control, Prevention (CDC). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs–worldwide, 2000–2004. MMWR. Morbidity and Mortality Weekly Report 55(11): 301–305.

Colditz, G.A., T.F. Brewer, C.S. Berkey, M.E. Wilson, E. Burdick, H.V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Journal of the American Medical Association 271(9): 698–702. doi:10.1001/jama.271.9.698.PubMedCrossRef

Connelly, D., Y. Veriava, S. Roberts, J. Tsotetsi, A. Jordan, E. DeSilva, S. Rosen, and M.B. DeSilva. 2007. Prevalence of HIV infection and median CD4 counts among health care workers in South Africa. South African Medical Journal 97(2): 115–120.PubMed

Corbett, E.L., C.J. Watt, N. Walker, D. Maher, B.G. Williams, M.C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163(9): 1009–1021. doi:10.1001/archinte.163.9.1009.PubMedCrossRef

Gandhi, N.R., A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547): 1575–1580. doi:10.1016/S0140-6736(06)69573-1.PubMedCrossRef

Garattini, S., and V. Bertele. 2007. How can we regulate medicines better? BMJ (Clinical Research Ed.) 335(7624): 803–805. doi:10.1136/bmj.39281.615706.94.CrossRef

Hanekom, W.A., H.M. Dockrell, T.H. Ottenhoff, T.M. Doherty, H. Fletcher, H. McShane, F.F. Weichold, D.F. Hoft, S.K. Parida, and U.J. Fruth. 2008. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Medicine 5(7): e145. doi:10.1371/journal.pmed.0050145.PubMedCrossRef

Huygen, K., J. Content, O. Denis, D.L. Montgomery, A.M. Yawman, R.R. Deck, C.M. DeWitt, I.M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J.P. Van Vooren, M.A. Liu, and J.B. Ulmer. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine 2(8): 893–898. doi:10.1038/nm0896-893.PubMedCrossRef

Ibanga, H.B., R.H. Brookes, P.C. Hill, P.K. Owiafe, H.A. Fletcher, C. Lienhardt, A.V. Hill, R.A. Adegbola, and H. McShane. 2006. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: Issues in study design. The Lancet Infectious Diseases 6(8): 522–528. doi:10.1016/S1473-3099(06)70552-7.PubMedCrossRef

Kamath, A.T., U. Fruth, M.J. Brennan, R. Dobbelaer, P. Hubrechts, M.M. Ho, R.E. Mayner, J. Thole, K.B. Walker, M. Liu, and P.H. Lambert. 2005. New live mycobacterial vaccines: The Geneva consensus on essential steps towards clinical development. Vaccine 23(29): 3753–3761. doi:10.1016/j.vaccine.2005.03.001.PubMedCrossRef

McElrath, M.J., S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, S.P. Buchbinder, M.N. Robertson, D.V. Mehrotra, S.G. Self, L. Corey, J.W. Shiver, and D.R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372(9653): 1894–1905. doi:10.1016/S0140-6736(08)61592-5.PubMedCrossRef

Minnies, D., T. Hawkridge, W. Hanekom, R. Ehrlich, L. London, and G. Hussey. 2008. Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. BMC Medical Ethics 9: 15. doi:10.1186/1472-6939-9-15.PubMedCrossRef

Morrison, J., M. Pai, and P.C. Hopewell. 2008. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: A systematic review and meta-analysis. The Lancet Infectious Diseases 8(6): 359–368. doi:10.1016/S1473-3099(08)70071-9.PubMedCrossRef

National Institute for Health and Clinical Excellence (NICE). 2006. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. http://www.nice.org.uk/nicemedia/pdf/CG033niceguideline.pdf. Accessed 4 April 2009.

Orme, I.M. 2005. The use of animal models to guide rational vaccine design. Microbes and Infection 7(5–6): 905–910. doi:10.1016/j.micinf.2005.03.008.PubMedCrossRef

Samson, K. 2008. Orphan economics: The downside of supplyside pharmacology. Annals of Neurology 64(3): A13–A16. doi:10.1002/ana.21432.CrossRef

Selgelid, M.J. 2005. Ethics and infectious disease. Bioethics 19(3): 272–289. doi:10.1111/j.1467-8519.2005.00441.x.PubMedCrossRef

Selgelid, M.J., P.M. Kelly, and A. Sleigh. 2008a. Ethical challenges in TB control in the era of XDR-TB. The International Journal of Tuberculosis and Lung Disease 12(3): 231–235.PubMed

Selgelid, M.J., P.M. Kelly, and A. Sleigh. 2008b. In International Public Health Policy and Ethics, ed. M. Boylan. Dordrecht: Springer.

Shisana, O., E.J. Hall, R. Maluleke, J. Chauveau, and C. Schwabe. 2004. HIV/AIDS prevalence among South African health workers. South African Medical Journal 94(10): 846–850.PubMed

Snider Jr., D.E. 2000. Ethical issues in tuberculosis vaccine trials. Clinical Infectious Diseases 30(Suppl 3): S271–S275. doi:10.1086/313872.PubMedCrossRef

Soliman, E.Z. 2008. The ethics of non-inferiority trials. Lancet 371(9616): 895. doi:10.1016/S0140-6736(08)60406-7. author reply 896-7.PubMedCrossRef

Tascon, R.E., M.J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D.B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nature Medicine 2(8): 888–892. doi:10.1038/nm0896-888.PubMedCrossRef

U.S. Department of Health, Education and Welfare. (1979). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Federal Register, 44(76): 23191–23197. http://ohsr.od.nih.gov/guidelines/belmont.html. Accessed 4 April 2009.

Williams, A., G.J. Hatch, S.O. Clark, K.E. Gooch, K.A. Hatch, G.A. Hall, K. Huygen, T.H. Ottenhoff, K.L. Franken, P. Andersen, T.M. Doherty, S.H. Kaufmann, L. Grode, P. Seiler, C. Martin, B. Gicquel, S.T. Cole, P. Brodin, A.S. Pym, W. Dalemans, J. Cohen, Y. Lobet, N. Goonetilleke, H. McShane, A. Hill, T. Parish, D. Smith, N.G. Stoker, D.B. Lowrie, G. Kallenius, S. Svenson, A. Pawlowski, K. Blake, and P.D. Marsh. 2005. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland) 85(1-2): 29–38. doi:10.1016/j.tube.2004.09.009.CrossRef

World Health Organization. 2007. Global tuberculosis control: surveillance, planning, financing. WHO Report. Geneva: World Health Organisation.

World Medical Association. 2008. Declaration of Helsinki. http://www.wma.net/e/policy/b3.htm. Accessed 4 April 2009.

Title: A New Vaccine for Tuberculosis: The Challenges of Development and Deployment
Authors: Helen A. Fletcher
Tony Hawkridge
Helen McShane
Publication date: 01-06-2009
Publisher: Springer Netherlands
Published in: Journal of Bioethical Inquiry / Issue 2/2009
Print ISSN: 1176-7529
Electronic ISSN: 1872-4353
DOI: https://doi.org/10.1007/s11673-009-9153-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A New Vaccine for Tuberculosis: The Challenges of Development and Deployment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Michael Boylan. ed. 2008. International public health policy and ethics

Recent Developments

Your Liberty or Your Life: Reciprocity in the Use of Restrictive Measures in Contexts of Contagion

Infectious Disease Ethics: Limiting Liberty in Contexts of Contagion

Responding to Global Poverty: Review Essay of Peter Singer, The Life you can Save

Should Persons Detained During Public Health Crises Receive Compensation?